Product Name

  • Name

    Dasatinib

  • EINECS 801-607-0
  • CAS No. 302962-49-8
  • Article Data47
  • CAS DataBase
  • Density 1.409 g/cm3
  • Solubility
  • Melting Point 275-286 °C
  • Formula C22H26ClN7O2S
  • Boiling Point
  • Molecular Weight 488.013
  • Flash Point
  • Transport Information
  • Appearance pale-yellow solid
  • Safety
  • Risk Codes
  • Molecular Structure Molecular Structure of 302962-49-8 (Dasatinib)
  • Hazard Symbols
  • Synonyms BMS 354825;BMS 35482513;Sprycel;Spyrcel;N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;
  • PSA 134.75000
  • LogP 3.46240

Synthetic route

1-(2-hydroxyethyl)piperazine
103-76-4

1-(2-hydroxyethyl)piperazine

2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302964-08-5

2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
With tetrabutylammomium bromide In acetonitrile at 30 - 80℃;97%
In propan-1-ol at 115 - 120℃; Temperature;93%
With copper(l) chloride In N,N-dimethyl-formamide at 65℃; for 2h; Temperature; Reagent/catalyst;91.6%
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-acetoxyethyl)-1-piperazinyl]-2-methyl- 4-pyrimidinyl]amino]-5-thiazolecarboxamide
1245157-85-0

N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-acetoxyethyl)-1-piperazinyl]-2-methyl- 4-pyrimidinyl]amino]-5-thiazolecarboxamide

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
With potassium carbonate In methanol; water at 60 - 65℃; for 3h; Solvent; Reagent/catalyst;96.4%
Stage #1: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-acetoxyethyl)-1-piperazinyl]-2-methyl- 4-pyrimidinyl]amino]-5-thiazolecarboxamide With water; sodium hydroxide at 50℃; for 2h;
Stage #2: With hydrogenchloride In water at 20 - 25℃; pH=4;		88.7%
Stage #1: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-acetoxyethyl)-1-piperazinyl]-2-methyl- 4-pyrimidinyl]amino]-5-thiazolecarboxamide With water; sodium hydroxide at 50℃; for 2h;
Stage #2: With hydrogenchloride In water at 20 - 25℃; pH=4;		88.7%
C20H24ClN5O4S

C20H24ClN5O4S

acetamidine hydrochloride
124-42-5

acetamidine hydrochloride

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
With sodium methylate In methanol at 65℃; for 4h; Temperature; Cooling with ice;95.3%
1-(2-hydroxyethyl)piperazine
103-76-4

1-(2-hydroxyethyl)piperazine

2,4-dichloro-2-methylpyrimidine
1780-26-3

2,4-dichloro-2-methylpyrimidine

2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide
302964-24-5

2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Stage #1: 1-(2-hydroxyethyl)piperazine; 2,4-dichloro-2-methylpyrimidine With potassium phosphate; 1-butyl-3-methylimidazolium aminoethanic acid salt at 80℃; for 1.5h;
Stage #2: 2-amino-N-(2-chloro-6-methylphenyl)-1.3-thiazole-5-carboxamide at 20 - 80℃; for 2h; Reagent/catalyst;		92.27%
Stage #1: 1-(2-hydroxyethyl)piperazine; 2,4-dichloro-2-methylpyrimidine With potassium phosphate; 1-butyl-3-methylimidazolium aminoethanic acid salt In N,N-dimethyl acetamide at 80℃; for 2h;
Stage #2: 2-amino-N-(2-chloro-6-methylphenyl)-1.3-thiazole-5-carboxamide In N,N-dimethyl acetamide at 80℃; for 3h; Solvent;		89.31%
Stage #1: 1-(2-hydroxyethyl)piperazine; 2,4-dichloro-2-methylpyrimidine With copper(l) iodide; dimethylaminoacetic acid; O4P(3-)*O4P(3-)*3K(1+) In N,N-dimethyl-formamide at 20℃; for 0.666667h;
Stage #2: 2-amino-N-(2-chloro-6-methylphenyl)-1.3-thiazole-5-carboxamide at 120℃; for 6h; Inert atmosphere;		88.41%
...Expand
1-(2-hydroxyethyl)piperazine
103-76-4

1-(2-hydroxyethyl)piperazine

2-(6-bromo-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-formamide
1245157-51-0

2-(6-bromo-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-formamide

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In butan-1-ol for 7h; Solvent; Time; Reflux;87.9%
With N-ethyl-N,N-diisopropylamine In isopropyl alcohol for 5h; Product distribution / selectivity; Reflux;73.6%
2-(4-(6-chloro-2-methylpyrimidin-4-yl)piperazin-1-yl)ethanol
127116-19-2

2-(4-(6-chloro-2-methylpyrimidin-4-yl)piperazin-1-yl)ethanol

2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide
302964-24-5

2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
In 1,4-dioxane at 75℃; for 3h; Concentration;83.2%
With potassium carbonate; palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl at 100 - 110℃; for 20h;
C29H30ClN7O3S
1245157-86-1

C29H30ClN7O3S

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Stage #1: C29H30ClN7O3S With water; sodium hydroxide at 50℃; for 2h;
Stage #2: With hydrogenchloride In water at 20 - 25℃; pH=4;		82.5%
Stage #1: C29H30ClN7O3S With water; sodium hydroxide at 50℃; for 2h;
Stage #2: With hydrogenchloride In water at 20 - 25℃; pH=4;		82.5%
C29H32ClN7O2S
1245157-70-3

C29H32ClN7O2S

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Stage #1: C29H32ClN7O2S With boron trichloride In dichloromethane at -15 - 20℃;
Stage #2: With water In dichloromethane Cooling with ice;		82.2%
With boron trichloride In dichloromethane at -15 - 20℃;82.2%
1-(2-hydroxyethyl)piperazine
103-76-4

1-(2-hydroxyethyl)piperazine

(2-(6-chloro-2-methylpyrimidine-4-ylamino)-N-(2-chloro-6-methylpbenyl)thiazole-5-carboxamide)

(2-(6-chloro-2-methylpyrimidine-4-ylamino)-N-(2-chloro-6-methylpbenyl)thiazole-5-carboxamide)

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
In 1-methyl-pyrrolidin-2-one at 65 - 100℃; for 1h; Inert atmosphere;82%
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formic acid
1245157-42-9

2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formic acid

2-chloro-6-methylaniline
87-63-8

2-chloro-6-methylaniline

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
With O-phenyl phosphorodichloridate; triethylamine In dichloromethane at 0 - 20℃; Product distribution / selectivity; Inert atmosphere;80.9%
With O-phenyl phosphorodichloridate; triethylamine In dichloromethane at 0 - 20℃; Reagent/catalyst; Inert atmosphere;80.9%
C24H30ClN7O2S2
1245157-78-1

C24H30ClN7O2S2

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Stage #1: C24H30ClN7O2S2 With boron trichloride In dichloromethane at -15 - 20℃;
Stage #2: With water In dichloromethane Cooling with ice;		80.7%
With boron trichloride In dichloromethane at -15 - 20℃;80.7%
C30H34ClN7O3S
1245157-72-5

C30H34ClN7O3S

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Stage #1: C30H34ClN7O3S With boron trichloride In dichloromethane at -15 - 20℃;
Stage #2: With water In dichloromethane Cooling with ice;		77.3%
With boron trichloride In dichloromethane at -15 - 20℃;77.3%
C26H34ClN7O3S
1245157-77-0

C26H34ClN7O3S

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Stage #1: C26H34ClN7O3S With boron trichloride In dichloromethane at -15 - 20℃;
Stage #2: With water In dichloromethane Cooling with ice;		72.5%
With boron trichloride In dichloromethane at -15 - 20℃;72.5%
C24H30ClN7O3S
1245157-75-8

C24H30ClN7O3S

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Stage #1: C24H30ClN7O3S With boron trichloride In dichloromethane at -15 - 20℃;
Stage #2: With water In dichloromethane Cooling with ice;		70.6%
With boron trichloride In dichloromethane at -15 - 20℃;70.6%
N-(2-chloro-6-methylphenyl)-2-((2-methyl-6-(piperazin-1-yl)pyrimidin 4-yl)amino)thiazole-5-carboxamide
910297-51-7

N-(2-chloro-6-methylphenyl)-2-((2-methyl-6-(piperazin-1-yl)pyrimidin 4-yl)amino)thiazole-5-carboxamide

2-bromoethanol
540-51-2

2-bromoethanol

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 110℃; for 16h;36%
methyl 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formate
1245157-35-0

methyl 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formate

2-chloro-6-methylaniline
87-63-8

2-chloro-6-methylaniline

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
With O-phenyl phosphorodichloridate; triethylamine In dichloromethane at 0 - 20℃; Inert atmosphere;32%
With O-phenyl phosphorodichloridate; triethylamine In dichloromethane at 0 - 20℃; Reagent/catalyst; Inert atmosphere;32%
2-chloro-6-methylphenyl isocyanate
40398-01-4

2-chloro-6-methylphenyl isocyanate

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: n-BuLi / tetrahydrofuran; hexane / 0.25 h / -78 - -75 °C
1.2: 86 percent / tetrahydrofuran; hexane / 2 h / -78 °C
2.1: NaH / dimethylformamide / 0.5 h
2.2: 95 percent / Bu4NI / dimethylformamide / 16 h / 20 °C
3.1: NaH / tetrahydrofuran / 0.5 h / 0 °C
3.2: 83 percent / tetrahydrofuran / 4 h / Heating
4.1: 99 percent / CF3CO2H; CF3SO3H / CH2Cl2 / 3 h / 20 °C
5.1: i-Pr2NEt / dioxane / 12 h / Heating
View Scheme
Multi-step reaction with 5 steps
1.1: n-BuLi / tetrahydrofuran; hexane / 0.25 h / -78 °C
1.2: 86 percent / tetrahydrofuran; hexane / 2 h / -78 °C
2.1: NaH / dimethylformamide / 0.5 h / 20 °C
2.2: 95 percent / tetrabutylammonium iodide / dimethylformamide / 16 h / 20 °C
3.1: NaH / tetrahydrofuran / 0.5 h / 0 °C
3.2: 83 percent / tetrahydrofuran / 4 h / Heating
4.1: 99 percent / TFA; triflic acid / CH2Cl2 / 3 h / 20 °C
5.1: diisopropylethylamine / dioxane / 12 h / Heating
View Scheme
2-chloro-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide
302964-11-0

2-chloro-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: NaH / dimethylformamide / 0.5 h
1.2: 95 percent / Bu4NI / dimethylformamide / 16 h / 20 °C
2.1: NaH / tetrahydrofuran / 0.5 h / 0 °C
2.2: 83 percent / tetrahydrofuran / 4 h / Heating
3.1: 99 percent / CF3CO2H; CF3SO3H / CH2Cl2 / 3 h / 20 °C
4.1: i-Pr2NEt / dioxane / 12 h / Heating
View Scheme
Multi-step reaction with 4 steps
1.1: NaH / dimethylformamide / 0.5 h / 20 °C
1.2: 95 percent / tetrabutylammonium iodide / dimethylformamide / 16 h / 20 °C
2.1: NaH / tetrahydrofuran / 0.5 h / 0 °C
2.2: 83 percent / tetrahydrofuran / 4 h / Heating
3.1: 99 percent / TFA; triflic acid / CH2Cl2 / 3 h / 20 °C
4.1: diisopropylethylamine / dioxane / 12 h / Heating
View Scheme
N-(4-methoxybenzyl)-2-chloro-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide
834888-63-0

N-(4-methoxybenzyl)-2-chloro-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: NaH / tetrahydrofuran / 0.5 h / 0 °C
1.2: 83 percent / tetrahydrofuran / 4 h / Heating
2.1: 99 percent / CF3CO2H; CF3SO3H / CH2Cl2 / 3 h / 20 °C
3.1: i-Pr2NEt / dioxane / 12 h / Heating
View Scheme
Multi-step reaction with 3 steps
1.1: NaH / tetrahydrofuran / 0.5 h / 0 °C
1.2: 83 percent / tetrahydrofuran / 4 h / Heating
2.1: 99 percent / TFA; triflic acid / CH2Cl2 / 3 h / 20 °C
3.1: diisopropylethylamine / dioxane / 12 h / Heating
View Scheme
N-(4-methoxybenzyl)-2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide
834888-64-1

N-(4-methoxybenzyl)-2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 99 percent / CF3CO2H; CF3SO3H / CH2Cl2 / 3 h / 20 °C
2: i-Pr2NEt / dioxane / 12 h / Heating
View Scheme
Multi-step reaction with 2 steps
1: 99 percent / TFA; triflic acid / CH2Cl2 / 3 h / 20 °C
2: diisopropylethylamine / dioxane / 12 h / Heating
View Scheme
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide n-butanolate

N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide n-butanolate

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
In ethanol; water at 0 - 80℃; for 5h; Product distribution / selectivity;
dasatinib monohydrate
863127-77-9

dasatinib monohydrate

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
In propan-1-ol; water at 0 - 5℃; for 1h; Product distribution / selectivity; Heating / reflux;
In water; isopropyl alcohol at 0 - 5℃; for 1h; Product distribution / selectivity; Heating / reflux;
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide iso-propanolate

N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide iso-propanolate

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
In water; N,N-dimethyl-formamide at 20 - 100℃;
1-(2-hydroxyethyl)piperazine
103-76-4

1-(2-hydroxyethyl)piperazine

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N-ethyl-N,N-diisopropylamine / butan-1-ol / 8 h / Reflux
2: triethylamine; O-phenyl phosphorodichloridate / dichloromethane / 0 - 20 °C / Inert atmosphere
View Scheme
Multi-step reaction with 3 steps
1.1: dichloromethane / 2.5 h / 30 °C
2.1: caesium carbonate / palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl / toluene / 16 h / Reflux
2.2: 0.17 h
2.3: 1 h / 10 - 15 °C
3.1: triethylamine; O-phenyl phosphorodichloridate / dichloromethane / 0 - 20 °C / Inert atmosphere
View Scheme
Multi-step reaction with 3 steps
1.1: N-ethyl-N,N-diisopropylamine / butan-1-ol / 8 h / Reflux
2.1: water; lithium hydroxide / water / 3 h / 50 °C
2.2: 20 °C / pH 6 - 6.5
3.1: triethylamine; O-phenyl phosphorodichloridate / dichloromethane / 0 - 20 °C / Inert atmosphere
View Scheme
2,4-dichloro-2-methylpyrimidine
1780-26-3

2,4-dichloro-2-methylpyrimidine

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: dichloromethane / 2.5 h / 30 °C
2.1: caesium carbonate / palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl / toluene / 16 h / Reflux
2.2: 0.17 h
2.3: 1 h / 10 - 15 °C
3.1: triethylamine; O-phenyl phosphorodichloridate / dichloromethane / 0 - 20 °C / Inert atmosphere
View Scheme
Multi-step reaction with 4 steps
1.1: dichloromethane / 2.5 h / 30 °C
2.1: caesium carbonate / palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl / toluene / 16 h / Reflux
2.2: 0.17 h
2.3: 1 h / 10 - 15 °C
3.1: water; lithium hydroxide / water / 3 h / 50 °C
3.2: 20 °C / pH 6 - 6.5
4.1: triethylamine; O-phenyl phosphorodichloridate / dichloromethane / 0 - 20 °C / Inert atmosphere
View Scheme
Multi-step reaction with 4 steps
1.1: dichloromethane / 2.5 h / 30 °C
2.1: caesium carbonate / palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl / toluene / 16 h / Reflux
2.2: 0.17 h
2.3: 1 h / 10 - 15 °C
3.1: sodium hydroxide; water / 20 °C
3.2: pH 6 - 6.5
4.1: triethylamine; O-phenyl phosphorodichloridate / dichloromethane / 0 - 20 °C / Inert atmosphere
View Scheme
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formyl chloride
1245158-43-3

2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formyl chloride

2-chloro-6-methylaniline
87-63-8

2-chloro-6-methylaniline

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In acetonitrile at 10 - 30℃; Product distribution / selectivity;
Stage #1: 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formyl chloride; 2-chloro-6-methylaniline In acetonitrile at 10 - 15℃;
Stage #2: With N-ethyl-N,N-diisopropylamine In acetonitrile at 30℃;		13.7 g
2-(6-(4-(2-benzoyloxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formic acid
1245157-82-7

2-(6-(4-(2-benzoyloxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formic acid

2-chloro-6-methylaniline
87-63-8

2-chloro-6-methylaniline

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: triethylamine; O-phenyl phosphorodichloridate / dichloromethane / 0 - 20 °C / Inert atmosphere
2.1: sodium hydroxide; water / 2 h / 50 °C
2.2: 20 - 25 °C / pH 4
View Scheme
C22H23ClN6O3S
1245158-47-7

C22H23ClN6O3S

2-chloro-6-methylaniline
87-63-8

2-chloro-6-methylaniline

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: N-ethyl-N,N-diisopropylamine / dichloromethane / 2 h / 0 - 20 °C
2.1: sodium hydroxide; water / 2 h / 50 °C
2.2: 20 - 25 °C / pH 4
View Scheme
2-(4-(6-chloro-2-methylpyrimidin-4-yl)piperazin-1-yl)ethanol
127116-19-2

2-(4-(6-chloro-2-methylpyrimidin-4-yl)piperazin-1-yl)ethanol

dasatanib
302962-49-8

dasatanib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: caesium carbonate / palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl / toluene / 16 h / Reflux
1.2: 0.17 h
1.3: 1 h / 10 - 15 °C
2.1: triethylamine; O-phenyl phosphorodichloridate / dichloromethane / 0 - 20 °C / Inert atmosphere
View Scheme
Multi-step reaction with 3 steps
1.1: caesium carbonate / palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl / toluene / 16 h / Reflux
1.2: 0.17 h
1.3: 1 h / 10 - 15 °C
2.1: water; lithium hydroxide / water / 3 h / 50 °C
2.2: 20 °C / pH 6 - 6.5
3.1: triethylamine; O-phenyl phosphorodichloridate / dichloromethane / 0 - 20 °C / Inert atmosphere
View Scheme
Multi-step reaction with 3 steps
1.1: caesium carbonate / palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl / toluene / 16 h / Reflux
1.2: 0.17 h
1.3: 1 h / 10 - 15 °C
2.1: sodium hydroxide; water / 20 °C
2.2: pH 6 - 6.5
3.1: triethylamine; O-phenyl phosphorodichloridate / dichloromethane / 0 - 20 °C / Inert atmosphere
View Scheme
dasatanib
302962-49-8

dasatanib

dasatinib N-oxide

dasatinib N-oxide

Conditions
ConditionsYield
With dihydrogen peroxide In 1-methyl-pyrrolidin-2-one; water at 20℃; for 18h;100%
With hydrogenchloride; dihydrogen peroxide In acetonitrile at 90℃; for 7h; Temperature; Sealed tube;80%
With dihydrogen peroxide In 1-methyl-pyrrolidin-2-one at 40℃;
dasatanib
302962-49-8

dasatanib

N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino]-1,3-thiazole-5-carboxamide dihydrogen bromide

N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino]-1,3-thiazole-5-carboxamide dihydrogen bromide

Conditions
ConditionsYield
With hydrogen bromide In ethanol; water at 70℃;97.7%
4-Ethoxyphenol
622-62-8

4-Ethoxyphenol

dasatanib
302962-49-8

dasatanib

dasatinib 4-ethoxyphenol co-crystal

dasatinib 4-ethoxyphenol co-crystal

Conditions
ConditionsYield
In water at 50℃;97%
dasatanib
302962-49-8

dasatanib

dasatinib monohydrate
863127-77-9

dasatinib monohydrate

Conditions
ConditionsYield
With ethanol; water at 80℃; for 2h; Large scale;96.44%
With water In ethanol at 75 - 80℃;
With water In ethanol at 0 - 80℃; for 5h;
With water In methanol Solvent; Heating;21 g
D-glucuronic acid
489-91-8, 528-16-5, 552-12-5, 577-46-8, 643-33-4, 2240-07-5, 6294-16-2, 10133-02-5, 18402-78-3, 18968-14-4, 21179-08-8, 23018-83-9, 33599-45-0, 33599-46-1, 46171-67-9, 46171-69-1, 46172-26-3, 70021-34-0, 71031-08-8, 104195-06-4, 106499-29-0, 124817-72-7

D-glucuronic acid

dasatanib
302962-49-8

dasatanib

N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide glucuronate

N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide glucuronate

Conditions
ConditionsYield
In methanol at 25 - 65℃; for 0.833333h; Time;95.6%
methanesulfonic acid
75-75-2

methanesulfonic acid

dasatanib
302962-49-8

dasatanib

N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino]-1,3-thiazole-5-carboxamide dimethanesulfonate salt

N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino]-1,3-thiazole-5-carboxamide dimethanesulfonate salt

Conditions
ConditionsYield
With hydrogen bromide In butanone at 60℃;93.7%
tert-butyldimethylsilyl chloride
18162-48-6

tert-butyldimethylsilyl chloride

dasatanib
302962-49-8

dasatanib

2-(6-(4-(2-(tert-butyldimethylsilyloxy)ethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
881381-50-6

2-(6-(4-(2-(tert-butyldimethylsilyloxy)ethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide

Conditions
ConditionsYield
With triethylamine; dmap In N,N-dimethyl-formamide at 20℃; for 1.5h;93.4%
cyclohexylsulfamic acid
100-88-9

cyclohexylsulfamic acid

dasatanib
302962-49-8

dasatanib

N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino]-1,3-thiazole-5-carboxamide monocyclamate salt

N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino]-1,3-thiazole-5-carboxamide monocyclamate salt

Conditions
ConditionsYield
In methanol at 70℃;93.4%
succinic acid anhydride
108-30-5

succinic acid anhydride

dasatanib
302962-49-8

dasatanib

4-(2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl) piperazin-1-yl)ethoxy)-4-oxobutanoic acid

4-(2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl) piperazin-1-yl)ethoxy)-4-oxobutanoic acid

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Schlenk technique;93%
With dmap In N,N-dimethyl-formamide at 50℃; for 18h; Inert atmosphere;90%
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere;90%
lauric acid
143-07-7

lauric acid

dasatanib
302962-49-8

dasatanib

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)ethyl dodecanoate

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)ethyl dodecanoate

Conditions
ConditionsYield
With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 25h; Inert atmosphere; Cooling with ice;91%
copper(II) nitrate trihydrate

copper(II) nitrate trihydrate

dasatanib
302962-49-8

dasatanib

C22H28ClCuN9O9S*NO3(1-)*H(1+)

C22H28ClCuN9O9S*NO3(1-)*H(1+)

Conditions
ConditionsYield
In methanol; dimethyl sulfoxide at 80℃; for 12h;91%
copper(II) nitrate trihydrate

copper(II) nitrate trihydrate

dasatanib
302962-49-8

dasatanib

C22H28ClCuN9O9S*HNO3

C22H28ClCuN9O9S*HNO3

Conditions
ConditionsYield
In methanol; dimethyl sulfoxide at 80℃; for 12h; Solvent; Temperature;91%
formic acid
64-18-6

formic acid

dasatanib
302962-49-8

dasatanib

C23H26ClN7O3S

C23H26ClN7O3S

Conditions
ConditionsYield
With dmap In N,N-dimethyl-formamide at 100℃; for 10h; Temperature;90.4%
1-decanoic acid
334-48-5

1-decanoic acid

dasatanib
302962-49-8

dasatanib

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)ethyl decanoate

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)ethyl decanoate

Conditions
ConditionsYield
With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 25h; Inert atmosphere; Cooling with ice;90.1%
Octanoic acid
124-07-2

Octanoic acid

dasatanib
302962-49-8

dasatanib

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)ethyl octanoate

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)ethyl octanoate

Conditions
ConditionsYield
With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 25h; Inert atmosphere; Cooling with ice;90%
carvacrol
499-75-2

carvacrol

dasatanib
302962-49-8

dasatanib

dasatinib carvacrol co-crystal

dasatinib carvacrol co-crystal

Conditions
ConditionsYield
In methanol at 50℃;90%
n-tetradecanoic acid
544-63-8

n-tetradecanoic acid

dasatanib
302962-49-8

dasatanib

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)ethyl tetradecanoate

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazin-1-yl)ethyl tetradecanoate

Conditions
ConditionsYield
With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 25h; Inert atmosphere; Cooling with ice;88.6%
phthalimide
136918-14-4

phthalimide

dasatanib
302962-49-8

dasatanib

N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-(1,3-dioxoisoindol-2-yl)ethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide

N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-(1,3-dioxoisoindol-2-yl)ethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide

Conditions
ConditionsYield
With diisopropyl azodicarboxylate; triphenylphosphine In tetrahydrofuran at 0 - 20℃;88%
With di-isopropyl azodicarboxylate; triphenylphosphine In tetrahydrofuran at 0 - 20℃; for 0.166667h;87.8%
toluene-4-sulfonic acid
104-15-4

toluene-4-sulfonic acid

dasatanib
302962-49-8

dasatanib

N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino]-1,3-thiazole-5-carboxamide p-toluenesulfonate salt

N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino]-1,3-thiazole-5-carboxamide p-toluenesulfonate salt

Conditions
ConditionsYield
In water; isopropyl alcohol at 70℃; Solvent;87.4%
In ethanol at 65 - 70℃; for 4h;
In ethanol Heating / reflux;
1-hexadecylcarboxylic acid
57-10-3

1-hexadecylcarboxylic acid

dasatanib
302962-49-8

dasatanib

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)pyrimidin-4-yl)piperazin-1-yl)ethyl palmitate

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)pyrimidin-4-yl)piperazin-1-yl)ethyl palmitate

Conditions
ConditionsYield
With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 25h; Inert atmosphere; Cooling with ice;86.5%
stearic acid
57-11-4

stearic acid

dasatanib
302962-49-8

dasatanib

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)pyrimidin-4-yl)piperazin-1-yl)ethyl stearate

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)pyrimidin-4-yl)piperazin-1-yl)ethyl stearate

Conditions
ConditionsYield
With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane; N,N-dimethyl-formamide at 25℃; Inert atmosphere; Cooling with ice;86.3%
acetic acid
64-19-7

acetic acid

dasatanib
302962-49-8

dasatanib

N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-acetoxyethyl)-1-piperazinyl]-2-methyl- 4-pyrimidinyl]amino]-5-thiazolecarboxamide
1245157-85-0

N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-acetoxyethyl)-1-piperazinyl]-2-methyl- 4-pyrimidinyl]amino]-5-thiazolecarboxamide

Conditions
ConditionsYield
With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 25℃; for 25h; Inert atmosphere; Cooling with ice;86%
citric acid triethyl ester
77-93-0

citric acid triethyl ester

dasatanib
302962-49-8

dasatanib

C22H26ClN7O2S*C12H20O7

C22H26ClN7O2S*C12H20O7

Conditions
ConditionsYield
In methanol at 20℃; for 3h;86%
Arachidic acid
506-30-9

Arachidic acid

dasatanib
302962-49-8

dasatanib

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)pyrimidin-4-yl)piperazin-1-yl)ethyl icosanoate

2-(4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)pyrimidin-4-yl)piperazin-1-yl)ethyl icosanoate

Conditions
ConditionsYield
With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane; N,N-dimethyl-formamide at 25℃; Inert atmosphere; Cooling with ice;85.3%
dasatanib
302962-49-8

dasatanib

3-bromodasatinib

3-bromodasatinib

Conditions
ConditionsYield
With hydrogen fluoride; antimony pentafluoride; sodium bromide at -20℃;84%

Dasatinib Specification

The CAS register number of 5-Thiazolecarboxamide,N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]- is 302962-49-8. It also can be called as Dasatinib and the IUPAC name about this chemical is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide. The molecular formula about this chemical is C22H26ClN7O2S and the molecular weight is 488.01. It belongs to the following product categories, such as Intermediates & Fine Chemicals; Pharmaceuticals; Tyrosine Kinase Inhibitors; Pharmaceutical intermediate and so on. This chemical is used as a new, oral, small-molecule Tyrosine Kinase Inhibitor (TKI) for the treatment of CML and antineoplastic.

Physical properties about 5-Thiazolecarboxamide,N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]- are: (1)ACD/LogP: 0.14; (2)ACD/BCF (pH 5.5): 1; (3)ACD/BCF (pH 7.4): 1; (4)ACD/KOC (pH 5.5): 1; (5)ACD/KOC (pH 7.4): 11.084; (6)#H bond acceptors: 9; (7)#H bond donors: 3; (8)#Freely Rotating Bonds: 6; (9)Polar Surface Area: 134.75Å2; (10)Index of Refraction: 1.688; (11)Molar Refractivity: 132.039 cm3; (12)Molar Volume: 346.405 cm3; (13)Polarizability: 52.344x10-24cm3; (14)Surface Tension: 73.791 dyne/cm.

The 5-Thiazolecarboxamide,N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]- is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. It is an oral dual BCR/ABL and Src family tyrosine kinases inhibitor approved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also being assessed for use in metastatic melanoma.

You can still convert the following datas into molecular structure:
(1)SMILES: Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl
(2)InChI: InChI=1/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
(3)InChIKey: ZBNZXTGUTAYRHI-UHFFFAOYAC
(4)Std. InChI: InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
(5)Std. InChIKey: ZBNZXTGUTAYRHI-UHFFFAOYSA-N

Related Products

Hot Products

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View